


Introduction to Halozyme Therapeutics

David Kang, Director, Drug Delivery and Innovation

Our Vision



Subcutaneous delivery with ENHANZE® can result in...

1

Decreased treatment burden

Treatment from hours to minutes¹

2

Fewer infusion related reactions²

3

New treatment options

Possible treatment in home, doctor's office, community hospital³

4

Strong patient preference

81-89% of patients prefer SC versus IV⁴

¹ Phesgo® Prescribing Information and DARZALEX Faspro® Prescribing Information.

² Lancet Haematol. "Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicenter, open-label, non-inferiority, randomised, phase 3 trial"; 2020.

³ VYVGART® Hytrulo Prefilled Syringe Prescribing Information

⁴ Pivot X, Gligorov J, Müller V, et al. "Patients' Preference for SC vs. IV", Annals of Oncology, 2014; O'Shaughnessy, J et al. Eur J Cancer. 2021 Jul;152:223-232; Rummel M, et al. Ann Oncol. 2017;28:836--842; Wasserman RL et al. J Allergy Clin Immunol. 2012;130:951--957